Pfizer’s 2023 – A Rough Ride, but Maybe a Ticket to a Better 2024
Over the past year, Pfizer (PFE) has seen its share price drop more than 36%, landing it in the S&P 500’s worst‑performing ranks. The dip mainly stemmed from a slump in COVID‑related product sales – vaccines steeply lost their fizz as demand waned.
Why Markets Might Have Overreacted
- Market Overreaction: Analysts like Saqib Iqbal suspect investors painted the company with too broad a brush, focusing on the pandemic slump while overlooking solid fundamentals.
- COVID Sales Over‑estimation: Pfizer’s own projections may have been overly optimistic about ongoing vaccine demand.
- Cheaper Than It Feels: When you crunch the numbers, the stock’s valuation looks like a bargain – a sign that the market hasn’t fully appreciated its value.
What’s Next for Pfizer?
The company will splash out its Q4 2023 earnings report on January 30. Stress‑testers are predicting EPS of -0.18, but that’s not the whole story.
- Sales Forecast 2024: Expected to hit between $58.5 billion and $61.5 billion, giving the firm a steady revenue base.
- Dividend Momentum: Pfizer announced a 42¢ dividend for Q1 – a 15th consecutive year of quarterly raises. With a current yield of 5.8%, it’s a sweet deal for income‑hungry investors.
The Bullish Takeaway
Despite the rough patch, many market watchers feel that Pfizer’s massive R&D pipeline and durable brand could pave the way for a rebound. Saqib Iqbal wraps it up: “It’s possible that Mr. Market wasn’t looking at the company’s fundamentals and probably overreacted to its price in 2023.” So, if you’re looking to hop aboard the pharma train for 2024, Pfizer might just be the train that’s getting ready for a smoother ride ahead.
Pfizer’s Big Moves: From Cancer Drugs to a New Takeover
Last month, Pfizer wrapped up a $43 billion purchase of Seagen, a biotech company that’s all about cutting‑edge cancer treatments. The deal also meant Pfizer got the green light from the FDA to launch Padcev, while partnering it with Merck’s Keytruda for patients battling advanced bladder cancer.
Why the Future May Happen to Be a Bit “Flat” for 2024
Finance analyst Saqib thinks the company might over‑estimate its COVID‑19 sales, which could keep revenue from shooting up this year. “I don’t expect a major rebound in Pfizer’s stock this year due to its challenges in sales and profitability,” he said. “But if you’re looking at a 5‑ to 10‑year horizon, Pfizer can be a solid diversifier.”
He added that as Pfizer expands its pipeline and pushes for more drug approvals, keeping a close eye on its share performance will be key.
What’s Going On with the Technicals?
- The 200‑day moving average is currently a tough hurdle; the stock is trading well below it.
- The Relative Strength Index (RSI) hovers around 50, so the market feels neutral.
- There are two important price levels to watch:
- Resistance at $30.20: If the stock breaks above this, it could shoot up to $33.99.
- Support at $27.60: A dip below this might push the price down to $25.73.
Want Daily Updates?
Get real‑time updates on this and other trading news straight to your phone—just hit subscribe now!
